Potential for biosimilars in rheumatology in Africa.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 37468221.
- Also identified by DOI 10.1136/ard-2023-224315.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Biosimilars are products which are highly similar to a reference biologic product (RBP). In Africa, regulatory frameworks for biosimilar approval are still in development in many countries and few biosimilars for rheumatic diseases are currently available. The use of biosimilar medicines in Africa provides an important opportunity to treat more rheumatology patients with biologic drugs. This editorial aims to shed a light on the potential benefits, challenges and current efforts, regarding the use of biosimilars in Africa in Rheumatology.
Medical subject headings
- Biosimilar Pharmaceuticals
- Rheumatology
- Rheumatic Diseases